Thus, the interplay of factors like immune checkpoint types expressed in tumors, their baseline expression levels, and changes with and without IFNγ stimulation can complicate cancer therapy using immune checkpoint inhibitors such as antibody-based drugs. Here, IFNG is linked to cancer.